Prevalence of a shortened prostacyclin half-life in plasma in healthy adults: results of a screening investigation.
Out of a total of 1,981 adults (956 males, 1,025 females; aged 16-71 yr) undergoing a screening investigation for elevated cholesterol only 3 healthy participants with pathologically enhanced prostaglandin 12 (PG12) degradation in plasma in vitro were discovered. The PG12 half-life in these three screenings was shorter than 60 sec and persisted during several follow-up checks. In one patient a familial defect was discovered. Diseases known to be associated with this disturbance in PG12 metabolism have been excluded. The mean half-life of PG12 in 1,978 people amounted to 10.71 +/- 1.93 min. It still needs to be clarified whether this rare disturbance in PG12 metabolism is causally related to, or only associated with, thromboembolic events. A possible predisposition should be elucidated by regular monitoring of affected persons.
Sinzinger
H
H
Department of Nuclear Medicine, University of Vienna, Ludwig Boltzmann Institute for Nuclear Medicine, Vienna, Austria.
Rauscha
F
F
Fitscha
P
P
Granegger
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D011464:Epoprostenol / Q000097:blood* / Q000235:genetics; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D010375:Pedigree; D012016:Reference Values
D011464:Epoprostenol